Ras association domain family member 5Genealiases: Maxp1 · NORE1 · NORE1A · NORE1B · RAPL
Q-omics provides the consensus-scored RASSF5 profile across patient tissues and cancer cell-line models. RASSF5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RASSF5 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, RASSF5 protein abundance shows 20,883 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, KIRC, and GBM as cancer lineages where RASSF5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RASSF5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RASSF5 survival associations across molecular data types. RASSF5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RASSF5 RNA expression–survival associations across cancer types. High RASSF5 expression shows unfavorable associations in UVM, KIRP and LGG, but favorable associations in HNSC, SKCM and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RASSF5 RNA expression.
This table summarizes RASSF5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RASSF5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RASSF5 shows lower tumor expression in HNSC, LUAD, COAD and LUSC and higher tumor expression in KIRC and THCA. The KIRC box plot shows higher RASSF5 RNA expression in tumor versus normal tissue (log2 FC = +1.821, t-test p < 0.001).
This table shows molecular features associated with RASSF5 in patient tissues and cancer cell lines. In patient samples, RASSF5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RASSF5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
